SG3 Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

SG3 Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,500	Closed	-$146K	–	1264
2020 Q3	$146K	Buy	+1,500	New	+$187K	0.01%	765
2020 Q1	–	Sell	-4,000	Closed	-$818K	–	477
2019 Q4	$818K	Buy	4,000 +2,500	+167%	+$456K	0.05%	116
2019 Q3	$120K	Hold	1,500	–	–	0.01%	261
2019 Q2	$142K	Hold	1,500	–	–	0.02%	310
2019 Q1	$128K	Buy	+1,500	New	+$125K	0.01%	247

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's RETA Position: Q4 2020 in Review

SG3 Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 1,500 shares — an estimated $146K sold.

SG3 Management first reported a position in RETA in Q1 2019 and held it in 5 quarters. The position peaked at $818K in Q4 2019. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

SG3 Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
SG3 Management sold 1,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $146K.
SG3 Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 5 quarters.
SG3 Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $818K in Q4 2019.
202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.